PRESERVE

Name No. For Patients with Purpose
PRESERVE 20-04

Resected oral cavity squamous cell carcinoma

The purpose of this study is to compare oncologic outcomes, functional outcomes, and quality of life (QoL) in patients treated with standard radiotherapy volumes vs. radiotherapy to the primary site and pathologically involved hemi-neck only, omitting radiation to the pN0 hemi-neck(s).


MK-3475-630/KEYNOTE-630

Name No. For Patients with Purpose
MK-3475-630/KEYNOTE-630 CTRIAL-IE 20-08

Melanoma

This is a randomized study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).